Spravato Nasal Spray Approved for Solo Use in Depression Treatment

Tejal Somvanshi

FDA cleared Spravato nasal spray as a standalone depression treatment, eliminating the need for combining it with daily antidepressant pills.

Photo Credit: NIAID (CC BY 2.0)

The nasal spray offers relief to one-third of 21 million Americans with severe depression who don't respond to standard antidepressant pills.

Photo Source: nasal spray (CC BY-SA 3.0)

Spravato works differently from traditional antidepressants targeting serotonin, though its exact antidepressant mechanism remains unknown.

Photo Source: Carsten Schertz (CC BY 2.0)

Patients must receive treatment at 3,000 certified clinics across the U.S., with mandatory two-hour monitoring due to potential side effects.

Photo Source: Lydia (CC BY 2.0)

Phase four trial showed improved depressive symptoms beginning about 24 hours after treatment, lasting through at least one month.

Photo Source: Sander van der Wel (CC BY-SA 2.0)

Over 140,000 patients worldwide have used Spravato since its 2019 launch, with more than a fifth achieving remission.

Photo Source: Kizzzbeth (CC BY-SA 2.0)

Sales reached $780 million in nine months of 2024, with Johnson & Johnson projecting annual revenue between $1-5 billion.

Photo Source: Raysonho (CC0 1.0)

Dr. Mattingly's St. Louis clinic treated 6,000 patients, with people starting to feel somewhat better within same day or next day.

Photo Source: ParkNicollet (CC BY-SA 3.0)

The spray cannot be picked up at pharmacies and requires strict medical supervision due to risks of dissociation and drowsiness.

Photo Source: Nils Werner (CC BY-NC-SA 2.0)

Patients now have flexibility to choose between spray-only treatment or combination therapy based on individual needs.

Photo Source: robin_24 (CC BY 2.0)